IWEUS Regenerative Healthcare Fund

Our Regenerative Healthcare Fund invests in health care businesses that show significant growth potential.

The Fund focuses on the acquisition of mid-market Current Good Manufacturing, Laboratory, and Tissue Practice (cGXP) laboratories. We expect the use of biologics in musculoskeletal procedures to be the largest revenue-generating segment in orthopedics, including musculoskeletal spine, disc biologics, cell culturing, and tissue engineering.